Integra LifeSciences (NASDAQ:IART – Get Free Report) updated its fourth quarter 2024 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.810-0.890 for the period, compared to the consensus estimate of 0.870. The company issued revenue guidance of $441.0 million-$451.0 million, compared to the consensus revenue estimate of $448.5 million. Integra LifeSciences also updated its FY 2024 guidance to 2.410-2.490 EPS.
Integra LifeSciences Trading Up 24.6 %
NASDAQ:IART traded up $4.74 on Monday, reaching $24.02. 1,265,210 shares of the company’s stock were exchanged, compared to its average volume of 1,087,620. The business has a fifty day moving average of $18.62 and a 200-day moving average of $24.52. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17. Integra LifeSciences has a 52-week low of $16.81 and a 52-week high of $45.42. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of 80.34, a price-to-earnings-growth ratio of 0.64 and a beta of 1.08.
Analyst Upgrades and Downgrades
IART has been the topic of a number of research reports. Citigroup reduced their target price on shares of Integra LifeSciences from $20.00 to $16.00 and set a “sell” rating on the stock in a report on Tuesday, October 1st. Bank of America lowered their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. JMP Securities reduced their price target on Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 30th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Finally, Morgan Stanley upped their target price on shares of Integra LifeSciences from $24.00 to $27.00 and gave the stock an “underweight” rating in a research note on Monday, July 15th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $26.50.
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
See Also
- Five stocks we like better than Integra LifeSciences
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Intel: Is Now the Time to Be Brave?
- 5 discounted opportunities for dividend growth investors
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- 3 Warren Buffett Stocks to Buy Now
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
